• Important Safety Information
• Prescribing Information

Resources

We sponsor a donation program in the US through a partnership with the National Organization of Rare Diseases (NORD). Patients can obtain an application by calling our toll free number: 1-877-ATON-549 (1-877-286-6549).

Perry RR, Keiser HR, Norton JA, et al. Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg. 1990;621-28.

Root RK. Pheochromocytoma — recent advances in diagnosis and treatment. West J Med, 1988;148:561-67.

Pheocromocytoma Paraganglioma Alliance website.

If you have a question about one of our products or patient programs, please call 1-877-ATON-549 (1-877-286-6549) or email us at patients@atonrx.com.

Important Safety Information
DEMSER^® (Metyrosine) inhibits tyrosine hydroxylase which catalyses the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). When DEMSER is used preoperatively, adequate intravascular volume must be maintained intraoperatively (especially after tumor removal) and postoperatively to avoid hypotension and decreased perfusion of vital organs. Life threatening arrhythmias may occur during anesthesia and surgery. DEMSER does not eliminate the danger of hypertensive crises or arrhythmias during manipulation of the tumor. DEMSER may add to the sedative effects of alcohol and other CNS depressants. Metyrosine crystalluria has been observed in a few patients. Patients should be urged to maintain water intake sufficient to achieve a daily urine volume of 2000mL or more. If crystalluria persists, the dosage should be reduced or the drug discontinued. DEMSER should be used with caution in patients with impaired hepatic or renal function, and in patients receiving phenothiazines or haloperidol. Safety of use in pregnancy has not been established and caution should be exercised when DEMSER is administered to a nursing woman. Safety and efficacy in pediatric patients under the age of 12 has not been established. The most common adverse reaction to DEMSER is moderate to severe sedation, which has been observed in almost all patients. Extrapyramidal signs such as drooling, speech difficulty and tremor have been reported in 10 percent of the patients, occasionally accompanied by trismus and frank Parkinsonism. Anxiety and psychic disturbances may occur. Diarrhea occurs in about 10 percent of patients and may be severe. Other adverse reactions have been reported.

PLEASE SEE FULL PRESCRIBING INFORMATION.